Loading
David Cameron is a breast oncologist who chairs the Breast International Group.
David Cameron is Professor of Oncology at the University of Edinburgh and Chair of the Breast International Group (BIG). His specialisms are breast cancer, adjuvant trials and trial governance. He chairs the network behind HERA, APHINITY and OlympiA and was a senior investigator on the long-term follow-up of HERA, published in The Lancet as the final analysis of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer. His other papers include BEATRICE, a phase 3 trial of adjuvant bevacizumab-containing therapy in triple-negative breast cancer, and updated results from MONALEESA-2 on first-line ribociclib plus letrozole in hormone receptor-positive advanced disease. His publications are listed on PubMed.
Shares HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab), HER2-positive breast cancer.
Shares HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab), Breast International Group (BIG), HER2-positive breast cancer.
Shares Breast International Group (BIG), HER2-positive breast cancer.
Shares HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab), HER2-positive breast cancer.
Shares APHINITY, Breast International Group (BIG), HER2-positive breast cancer.
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, HER2-positive breast cancer.
Shares APHINITY, HER2-positive breast cancer.
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, HER2-positive breast cancer.